Enanta Stumbles In Trying To Show Better FXR Agonist Profile In NASH

 
• By Joseph Haas

Enanta hoped its Phase II study would indicate a better efficacy and/or tolerability profile for EDP-305 compared to other FXR agonists for NASH, including Intercept’s OCA. Despite the inconclusive data, it plans a longer Phase IIb study.

Blood sample with requisition form for liver enzyme (AST, ALT) test - Image
Enanta's NASH drug lowered ALT levels, but the fuller picture is unclear

More from Clinical Trials

More from R&D